SEC Form 4 · accession 0001209191-16-156413

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 21, 2016

Accepted (ET)

Dec 22, 2016 · 10:30 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Dec 21, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Dec 21, 2016	S	4,100	$73.65	D	270,625	D
Common Stock^F2,F4	Dec 21, 2016	S	1,300	$74.35	D	269,325	D
Common Stock^F2,F5	Dec 21, 2016	S	800	$75.61	D	268,525	D
Common Stock^F2,F6	Dec 21, 2016	S	300	$76.39	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401k
Common Stock	holding	—	—		—	78,200	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$36.30	Dec 21, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	21,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $73.65 (range $73.06 to $74.05).
F4Open market sales reported on this line occurred at a weighted average price of $74.35 (range $74.07 to $75.00).
F5Open market sales reported on this line occurred at a weighted average price of $75.61 (range $75.12 to $76.03).
F6Open market sales reported on this line occurred at a weighted average price of $76.39 (range $76.13 to $76.52).
F7Fully vested.